-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, in the pharmaceutical industry, pharmaceutical companies have begun to disclose their annual performance forecasts for 2021
.
On the whole, most of the companies are pre-happy
.
Such as Hualan Co.
, Ltd.
, Yanan Bikang, Kaipu Biology, Dongbao Biology, Zuoli Pharmaceutical,
etc.
Recently, another group of companies announced their performance forecasts, and it is worth noting that these companies that issued forecasts on the same day also saw a pre-increase in net profit
.
On January 18, WuXi PharmaTech released a performance forecast, predicting that its net profit in 2021 will increase by 2.
013 billion yuan to 2.
072 billion yuan, a year-on-year increase of 68%-70%
.
According to the announcement, its net profit growth was mainly due to the integrated chemical business segment, the continuous construction of the "integrated, end-to-end" CRDMO business, and the strong demand for orders, which accelerated the growth of annual sales revenue; Laboratory analysis and testing business and clinical CRO/SMO business, biology business and small molecule drug discovery services under the chemical business also continued to maintain strong growth momentum
.
On the same day, Yabao Pharmaceutical's performance forecast showed that it is expected that the net profit attributable to shareholders of listed companies in 2021 will be 165 million to 190 million yuan, an increase of 53.
68% to 76.
96% year-on-year
.
The announcement shows that in 2021, the company will focus on high-margin core products and increase promotion efforts.
Dingguier umbilical paste, swelling and pain relief paste, barley spleen gel and children's clearing throat and antipyretic oral liquid and other high-margin products have achieved relatively high revenue.
Under the influence of the large growth, the company's operating performance in 2021 will increase significantly
.
Meihua Bio's 2021 annual performance forecast shows that the net profit attributable to shareholders of listed companies is expected to be 2.
30 billion yuan to 2.
40 billion yuan, an increase of 1.
31794 billion yuan to 1.
41794 billion yuan compared with the same period of the previous year, a year-on-year increase of 134% to 144%
.
The performance growth of Meihua Biological in 2021 is mainly due to the increase in operating profit and the increase in main business income and profit.
.
In addition, the performance forecast released by Jiuzhou Pharmaceutical is also in line with market expectations.
It is expected that the net profit attributable to shareholders of listed companies in 2021 will be 609 million yuan to 685 million yuan, an increase of 228 million yuan to 304 million yuan compared with the same period last year.
100 million yuan, an increase of 60% to 80% year-on-year
.
It is reported that in the announcement, the company's performance maintained rapid growth, it clearly stated that it was mainly due to the steady improvement of the company's R&D capabilities and delivery capabilities, and the continuous expansion of CDMO business customer pipelines and product pipelines
.
Of course, some people are happy, and naturally some people are worried.
There are also many pharmaceutical and biological companies that have pre-reduced annual performance
.
For example, Berry Gene is expected to increase losses
.
As early as October 30 last year, it released its performance pre-loss.
It is expected that the net profit for the year will be -90 million yuan to -60 million yuan.
Compared with the same period last year, the net profit will drop by 143% to 128%
.
In general, medicine is a rigid demand industry.
With the upgrade of health consumption, the industry has long-term growth momentum; at the same time, with the improvement of medical demand satisfaction and penetration rate, China's pharmaceutical industry will accelerate its growth, with a long logical cycle and Strong enough certainty, so although some pharmaceutical companies performed poorly last year, in the long run, the development of related pharmaceutical companies is still worth looking forward to
.
.
On the whole, most of the companies are pre-happy
.
Such as Hualan Co.
, Ltd.
, Yanan Bikang, Kaipu Biology, Dongbao Biology, Zuoli Pharmaceutical,
etc.
Recently, another group of companies announced their performance forecasts, and it is worth noting that these companies that issued forecasts on the same day also saw a pre-increase in net profit
.
On January 18, WuXi PharmaTech released a performance forecast, predicting that its net profit in 2021 will increase by 2.
013 billion yuan to 2.
072 billion yuan, a year-on-year increase of 68%-70%
.
According to the announcement, its net profit growth was mainly due to the integrated chemical business segment, the continuous construction of the "integrated, end-to-end" CRDMO business, and the strong demand for orders, which accelerated the growth of annual sales revenue; Laboratory analysis and testing business and clinical CRO/SMO business, biology business and small molecule drug discovery services under the chemical business also continued to maintain strong growth momentum
.
On the same day, Yabao Pharmaceutical's performance forecast showed that it is expected that the net profit attributable to shareholders of listed companies in 2021 will be 165 million to 190 million yuan, an increase of 53.
68% to 76.
96% year-on-year
.
The announcement shows that in 2021, the company will focus on high-margin core products and increase promotion efforts.
Dingguier umbilical paste, swelling and pain relief paste, barley spleen gel and children's clearing throat and antipyretic oral liquid and other high-margin products have achieved relatively high revenue.
Under the influence of the large growth, the company's operating performance in 2021 will increase significantly
.
Meihua Bio's 2021 annual performance forecast shows that the net profit attributable to shareholders of listed companies is expected to be 2.
30 billion yuan to 2.
40 billion yuan, an increase of 1.
31794 billion yuan to 1.
41794 billion yuan compared with the same period of the previous year, a year-on-year increase of 134% to 144%
.
The performance growth of Meihua Biological in 2021 is mainly due to the increase in operating profit and the increase in main business income and profit.
.
In addition, the performance forecast released by Jiuzhou Pharmaceutical is also in line with market expectations.
It is expected that the net profit attributable to shareholders of listed companies in 2021 will be 609 million yuan to 685 million yuan, an increase of 228 million yuan to 304 million yuan compared with the same period last year.
100 million yuan, an increase of 60% to 80% year-on-year
.
It is reported that in the announcement, the company's performance maintained rapid growth, it clearly stated that it was mainly due to the steady improvement of the company's R&D capabilities and delivery capabilities, and the continuous expansion of CDMO business customer pipelines and product pipelines
.
Of course, some people are happy, and naturally some people are worried.
There are also many pharmaceutical and biological companies that have pre-reduced annual performance
.
For example, Berry Gene is expected to increase losses
.
As early as October 30 last year, it released its performance pre-loss.
It is expected that the net profit for the year will be -90 million yuan to -60 million yuan.
Compared with the same period last year, the net profit will drop by 143% to 128%
.
In general, medicine is a rigid demand industry.
With the upgrade of health consumption, the industry has long-term growth momentum; at the same time, with the improvement of medical demand satisfaction and penetration rate, China's pharmaceutical industry will accelerate its growth, with a long logical cycle and Strong enough certainty, so although some pharmaceutical companies performed poorly last year, in the long run, the development of related pharmaceutical companies is still worth looking forward to
.
